ThermoGenesis (THMO)
(Delayed Data from OTC)
$0.13 USD
-0.06 (-32.21%)
Updated Aug 12, 2024 09:30 AM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Brokerage Reports
ThermoGenesis Holdings, Inc. [THMO]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Potential For First CDMO Customer to Come in Q3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Looking Ahead to First CDMO Partnerships; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
CDMO Expected to Come Online in Q2; Adjust to $5.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Looking Ahead to CDMO Launch in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
CDMO Expected to Come Online in 2023; Lower $1.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Signs of Recovery in Cord Blood; Awaiting CDMO Plans; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Pandemic Recovery Underway; New Products for Commercial Cell Processing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Continued Challenges Due to COVID; Looking to Start CMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Long-Term Thesis Intact Despite Pandemic Headwinds; Adjusting PT to $8.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
COVID-19 Kits Nearing Launch; Pandemic Impact on Sales; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Promising Antibodies Against COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
Rapid COVID-19 Diagnostic Approved; Higher $9.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ThermoGenesis Holdings, Inc.
Industry: Medical - Instruments
New Partnerships to Provide the Growth Drivers in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|